The E3 Ubiquitin Ligase WWP1 Selectively Targets HER4 and Its Proteolytically Derived Signaling Isoforms for Degradation by Feng, S.-M. et al.
MOLECULAR AND CELLULAR BIOLOGY, Feb. 2009, p. 892–906 Vol. 29, No. 3
0270-7306/09/$08.000 doi:10.1128/MCB.00595-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
The E3 Ubiquitin Ligase WWP1 Selectively Targets HER4 and Its
Proteolytically Derived Signaling Isoforms for Degradation
Shu-Mang Feng,1 Rebecca S. Muraoka-Cook,1,2 Debra Hunter,1 Melissa A. Sandahl,1
Laura S. Caskey,1 Keiji Miyazawa,4 Azeddine Atfi,5 and H. Shelton Earp III1,3*
UNC Lineberger Comprehensive Cancer Center,1 Department of Genetics,2 and Department of Medicine and Pharmacology,3
University of North Carolina at Chapel Hill, School of Medicine, Chapel Hill, North Carolina 27599; Department of
Molecular Pathology, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan4; and INSERM U 482,
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In general, epidermal growth factor receptor family members stimulate cell proliferation. In contrast, at
least one HER4 isoform, JM-a/Cyt1, inhibits cell growth after undergoing a two-step proteolytic cleavage that
first produces a membrane-anchored 80-kDa fragment (m80HER4) and subsequently liberates a soluble 80-kDa
fragment, s80HER4. Here we report that s80HER4 Cyt1 action increased the expression of WWP1 (for WW
domain-containing protein 1), an E3 ubiquitin ligase, but not other members of the Nedd4 E3 ligase family. The
HER4 Cyt1 isoform contains three proline-rich tyrosine (PY) WW binding motifs, while Cyt2 has only two. WWP1
binds to all three Cyt1 PY motifs; the interaction with PY2 found exclusively in Cyt1 was strongest.
WWP1 ubiquitinated and caused the degradation of HER4 but not of EGFR, HER2, or HER3. The HER4-
WWP1 interaction also accelerated WWP1 degradation. Membrane HER4 (full length and m80HER4, the
product of the first proteolytic cleavage) were the preferred targets of WWP1, correlating with the membrane
localization of WWP1. Conversely s80HER4, a poorer WWP1 substrate, was found in the cell nucleus, while
WWP1 was not. Deletion of the C2 membrane association domain of WWP1 allowed more efficient s80HER4
degradation, suggesting that WWP1 is normally part of a membrane complex that regulates HER4 membrane
species levels, with a predilection for the growth-inhibitory Cyt1 isoform. Finally, WWP1 expression diminished
HER4 biologic activity in MCF-7 cells. We previously showed that nuclear s80HER4 is ubiquitinated and
degraded by the anaphase-promoting complex, suggesting that HER4 ubiquitination within specific cellular
compartments helps regulate the unique HER4 signaling capabilities.
The epidermal growth factor receptor (EGFR) family of
receptor tyrosine kinases (RTKs) consists of EGFR/HER1/
ErbB1, ErbB2/HER2, ErbB3/HER3, and ErbB4/HER4. All
family members have a ligand-binding ectodomain, a single
transmembrane segment, an intracellular tyrosine kinase
domain, and a tyrosine-rich carboxy terminus. Ten ligands
from two related ligand families, the epidermal growth fac-
tor (EGF) and heregulin/neuregulin families, bind to EGFR
family RTKs. Ligand-dependent homo- and heterodimeriza-
tion results in kinase activation and cross-phosphorylation. Al-
though HER1 and HER4 are capable of both homo- and
heterodimerization under most conditions, HER2 and HER3
are obligate heterodimeric partners, since HER2 does not bind
any known ligand, and HER3 is devoid of intrinsic kinase
activity. The activated receptor complexes exhibit multiple sig-
naling capabilities including stimulation of canonical mitogen-
activated protein kinase, phosphatidylinositol 3-kinase, and/or
STAT signaling pathways (10, 41, 47).
All four EGFR family members play a role in regulating
cardiovascular, neuronal, and epithelial development. Null
mutations of any of the EGFR family members result in em-
bryonic lethality. Despite these similarities, HER4 exhibits
unique biological activities that set it apart from the rest of the
EGFR family. Whereas EGFR, HER2, and HER3 stimulate
cellular proliferation, survival, and migration (41), HER4 ex-
pression and activation often correlates with decreased cell
growth and differentiation (13, 33, 34, 43). In studies of human
breast cancer, aberrant expression or activity of EGFR, HER2,
and HER3 appears to contribute to tumor progression and
correlate with poorer patient outcomes (10, 17). In contrast,
HER4 expression correlates with estrogen receptor positivity,
lower tumor grade, and a more favorable prognosis in most
studies (3, 21, 37, 46, 51, 52, 57); however, some studies report
a poorer prognosis in subsets of HER4-positive breast cancers
(4, 27). These paradoxical findings regarding HER4 expression
in breast cancer may relate to the unique cellular biology of
HER4; specifically, variant isoforms of HER4 are generated by
alternative splicing that exhibit properties unique to HER4.
HER4 RNA is alternatively spliced to yield at least four
isoforms that differ in the sequence encoding two specific re-
gions of HER4. The first is the receptor juxtamembrane do-
main, in which alternative splicing gives rise to either the JM-a
or the JM-b isoforms (12). Alternative splicing within the re-
gion encoding the midcytoplasmic domain results in the pro-
duction of either the CYT-1 or CYT-2 HER4 isoform (11).
Thus, four distinct HER4 isoforms have been observed: JM-
a/Cyt1, JM-a/Cyt2, JM-b/Cyt1, and JM-b/Cyt2. Each isoform
alters HER4 signaling in some manner affecting stability, turn-
over, cellular localization, and interaction with HER4 down-
stream elements (15, 19). Factors regulating “downregulation”
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of the ligand binding or localization-specific stability of HER4
and its proteolytic products (see below) are not yet under-
stood. However, it is clear that ligand binding does not lead to
the well-studied clathrin-coated pit internalization mechanism
characteristic of the EGFR.
One unique aspect of HER4 signaling among the EGFR
family is the proteolytic cleavage that occurs upon activation,
generating an 80-kDa fragment. Upon ligand binding or phor-
bol myristate acetate (PMA) treatment, HER4 is cleaved by a
tumor necrosis factor-converting enzyme (TACE)-like activity,
releasing the extracellular domain and leaving an 80-kDa
membrane-associated HER4 (m80) (40, 54). This is followed
by intramembranous HER4 cleavage by -secretase, releasing
a soluble 80-kDa fragment, s80HER4, into the cytoplasm (25,
34). The intracellular domain contains canonical nuclear local-
ization and export sequences and in fact translocates to the
nucleus in a manner requiring an active tyrosine kinase (33).
Evidence is accumulating that the nuclear s80HER4 participates
in gene transcriptional regulation and growth control (13, 33,
34, 42, 56). Alternative splicing has a direct influence on HER4
cleavage, because only the JM-a isoform, but not JM-b, is
susceptible to proteolytic cleavage by TACE (8, 40).
Also unique to HER4 within this RTK family is the presence
of protein-rich, WW-domain binding motifs known as PY se-
quences (PPXY, where X is any amino acid). WW domains are
globular motifs consisting of 40 amino acids, two of which are
highly conserved tryptophans (WW) (49). HER4 has been
reported to interact with several WW containing proteins, in-
cluding Itch (27), YAP (23), and WWOX (2). Again, alterna-
tive splicing of HER4 may directly affect the extent or strength
of WW-domain binding. The HER4 Cyt1 isoform harbors 16
amino acids (SEIGHSPPPAYTPMSG), that are absent in the
HER4Cyt2 isoform. This Cyt1-specific sequence harbors a
WW-domain binding motif (PPAY), which also overlaps with
a previously described phosphatidylinositol 3-kinase binding
region (11). In all, HER4Cyt1 has three PY motifs in its cyto-
plasmic domain, whereas the HER4 Cyt2 isoform has only two
PY motifs. The consequences of the differential in PY domains
between Cyt1 and Cyt2, and the potential effects upon HER4
interaction with WW-domain containing proteins are not yet
known but are profound since the Cyt1 isoform inhibits breast
epithelial cell growth, while the Cyt2 isoform does not (R. S.
Muraoka-Cook et al., unpublished data).
A full understanding of EGFR family biologic action must
include knowledge regarding signal termination and, in the last
decade, it has become apparent that receptor ubiquitination
plays a general role in protein metabolism and a specific role in
EGFR family signaling. Ubiquitination is a posttranslational
modification that can (i) direct proteins for degradation by the
26S proteasome; (ii) target plasma membrane proteins for
endocytosis, sorting, and destruction in the lysosome; or (iii)
alter the function of proteins involved in signal transduction,
transcription, or DNA repair. The ubiquitination requires
three critical enzymes: a ubiquitin-activating enzyme (E1), a
ubiquitin-conjugating enzyme (E2), and a ubiquitin ligase
(E3). The E3 ubiquitin ligase provides substrate specificity and
catalyzes isopeptide bond formation between ubiquitin and the
substrate (16, 35). There are more than 500 E3 ligases and
several target EGFR family members for degradation. Upon
EGF stimulation, EGFR associates with an E3 ligase, Cbl, and
undergoes ubiquitination, which facilitates its lysosomal sort-
ing and eventual degradation (26, 59). The E3 ligase CHIP (for
carboxyl terminus Hsc70-interacting protein) associates with
ErbB2 and induces ErbB2 ubiquitination and downregulation
(58, 61). The E3 ligase Nrdp1 (for neuregulin receptor degrad-
ing protein 1) associates with ErbB3 and stimulates its ubiq-
uitination and degradation by proteasomes (9, 39). Very re-
cently, it has been reported that WW domain containing E3
ligase, Aip4/Itch, results in HER4 degradation (36).
Our previous work demonstrated that s80HER4 expression in
multiple breast cancer cell lines translocates into nucleus, reg-
ulates the cell cycle (31, 48), inhibits cell proliferation (13), and
induces differentiation (33). In the course of initial microarray
gene expression studies, we noted a marked increase in the
WWP1 transcript in HC11 mouse breast cell lines stably
expressing GFP-s80HER4Cyt1 compared to HC11 expressing
green fluorescent protein (GFP) alone. In the experiments
described here, we establish that HER4 and s80HER4 bind
specifically to WWP1 via the HER4 cytoplasmic PY motifs.
The E3 ligase activity specifically ubiquitinates HER4 with a
preference for membrane-associated species and Cyt1 isoform
leading to degradation; EGFR, HER2, and HER3 are not
WWP1 targets.
MATERIALS AND METHODS
Cell culture. COS-7 cells were grown in Dulbecco modified Eagle medium
(Gibco-BRL) supplemented with 10% fetal bovine serum. MCF-7 cells were
grown in minimal essential medium with 10% fetal bovine serum plus 5 g of
insulin (Gibco-BRL)/ml, 100 U of nonessential amino acids (Invitrogen)/ml,
sodium pyruvate (1 mM), and antibiotics at 37°C with 5% CO2. HC11 cells and
their derivatives were cultured as previously described (13). Where indicated, the
following factors were added: recombinant heregulin1 (a gift from Genentech),
MG132 (Peptide Institute, Inc., Minoh-shi Osaka, Japan), bafilomycin A1 (LC
Laboratories, Woburn, MA), GM6001 (Calbiochem, San Diego, CA), and cy-
cloheximide (CHX) and PMA (both from Sigma-Aldrich).
Plasmids, transfection, and small interfering RNA (siRNA). The following
constructs were described previously: pLXSN-HER4 (JM-a, Cyt1) (43), pcDNA3-
s80Cyt2 (33), pcDNA3-Flag-WWP1 and pcDNA3-Flag-WWP1(C890A) (22), a
variety of WWP1 deletion constructs (44), CMV-HA-Yap2 (30), and pcDNA4-
Flag-WWOX (28). pShuttle-CMV-GFP-CTHER4 (HER4 residues 989 to 1308)
and pShuttle-CMV-GFP-s80HER4 (HER4 residues 676 to 1308) were gener-
ated from pMSCV-GFP-CTHER4 and pMSCV-GFP-s80HER4 (13), respectively.
pShuttle-CMV-KDOHER4 expressing HER4 residues 676 to 995, was generated by
removing the HindIII fragment from pShuttle-CMV-GFP-s80HER4. An EcoRI/
BamHI fragment from pShuttle-CMV-GFP-s80Cyt1 was used to replace the EcoRI/
BamHI fragment in pcDNA3-s80Cyt2 to generate pcDNA3-s80Cyt1. A K751 to R
point mutation to eliminate kinase activity of s80 was generated in pShuttle-CMV-
GFP-s80Cyt1 by using GeneEditor (Promega, Madison, WI) and the primer 5-CC
TGTGGCTATTAGGATTCTTAATGAG-3 (the mutated nucleotide is under-
lined), thus generating pShuttle-CMV-GFP-s80Cyt1KRHER4. pcDNA3-m80Cyt1
expressing HER4 residues 632 to 1308, including the transmembrane domain, was
constructed by replacing the AflII/KpnI fragment of pcDNA3-s80Cyt1 with the
corresponding PCR amplified m80 fragment cDNA. To delete PY1 (1031-PPPIY-
1035), thus generating pcDNA3-s80Cyt2PY1, two-step PCR-mediated mutagene-
sis was performed using Pfu DNA polymerase (Stratagene, La Jolla, CA) and the
following two sets of primers: primers F1 (5-GGT ATT TGG GTA CCT GAA G-3
[the KpnI site is underlined] and R1 (5-GAG TCA ATT CTT GCT CTG GAA
GTG ATG TTG AAA GCC TGA GGG AC-3) and primers F2 (5-GTC CCT
CAG GCT TTC AAC ATC ACT TCC AGA GCA AGA ATT GAC TC-3) and R2
(5-CAC AAT AGG CCG GAT CCG CC-3 [the BamHI site is underlined]). The
two overlapping PCR products were amplified by using the primers F1 and R2, and
a KpnI/BamHI fragment was used to replace the corresponding fragment in
pcDNA3-s80Cyt2. pcDNA3-s80Cyt2PY3 was generated by using PCR-mediated
mutagenesis with Pfu DNA polymerase and the primers 5-CCT TTG CCA ACA
CCT TGG-3 and 5-GCT CTA GAT TAC ACC ACA GTA TTC CGG TGT CTT
AGC ACA GTG CCT GGC TTC AGG-3; the BamHI/XbaI fragment was used to
replace the corresponding fragment of pcDNA3-s80Cyt2. The KpnI/BamHI frag-
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FIG. 1. HER4-induced expression of WWP1 results in degradation of HER4 and its cleavage product, m80/s80HER4. (A) HC11 cells stably
expressing GFP-s80 or GFP were used to extract total RNA for microarray analysis. Data mining for specific transcripts encoding the indicated
WW-containing proteins was performed. The ratios of the mRNA levels in GFP-s80-expressing cells and those in GFP-expressing cells are shown.
Experiments were performed in triplicate on three independent samples. Values represent the average ratio; the error bars represent the standard
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ment of pcDNA3-s80Cyt2PY3 was replaced with the corresponding fragment from
pcDNA3-s80Cyt2PY1 to generate pcDNA3-s80Cyt2PY1,3 (both PPPIY
and PPPPY deleted). All constructs were verified by DNA sequencing. Trans-
fection of COS-7 cells was performed by using FuGENE 6 (Roche Molecular
Biochemicals) according to the manufacturer’s protocol. Transfection of MCF-7
cells was performed by electroporation using reagents from Amaxa Biosystems
(Gaithersburg, MD). The control siRNA (ON-TARGETplus Non-Targeting
Pool) and WWP1-specific siRNA (ON-TARGETplus SMART Pool) were from
Dharmacon RNA Technologies (Lafayette, CO). The control or WWP1 specific
siRNA was electroporated into MCF-7 cells by using Amaxa Biosystems
(Gaithersburg, MD) reagents. Luciferase assays were performed 48 h after trans-
fection using 200 g of protein (luciferase assay kit; Promega, Madison, WI)
according to the manufacturer’s instructions.
Cell fractionation, immunoprecipitation, and immunoblot analysis. Mem-
brane and soluble fractions of cells were prepared by using ultracentrifugation as
previously described (53). For immunoprecipitation and/or immunoblot analysis,
cells were washed with cold phosphate-buffered saline and lysed in regular lysis
buffer (RLB; 20 mM Tris-HCl [pH 7.5], 50 mM NaF, 10% glycerol, 0.5%
Nonidet P-40, 1 mM EDTA, 1 mM EGTA, 20 mM -glycerophosphate,137 mM
NaCl, 1 mM Na3VO4, and protease inhibitor cocktail [Roche]) or high-salt lysis
buffer (20 mM HEPES, 50 mM NaF, 10% glycerol, 1% Triton, 5 mM EDTA, 500
mM NaCl, 1 mM Na3VO4, and protease inhibitors cocktail) and cleared by
centrifugation (13,000  g for 10 min at 4°C). Lysates were used for immuno-
precipitation for 3 h or overnight at 4°C with protein A/G or protein A agarose
beads (Santa Cruz Biotechnologies, Santa Cruz, CA) and mouse anti-FLAG
antibody (Sigma, Louis, MO) or rabbit HER4 antibody (13). Immunocomplexes
or protein lysates were separated on 8% sodium dodecyl sulfate (SDS)-poly-
acrylamide gels and transferred to polyvinylidene difluoride membranes (Bio-
Rad). Membranes were probed with antibodies against the following proteins:
Flag (mouse anti-Flag antibody; Sigma); HER4 (HFR-1) and HER3 (Ab-1) from
NeoMarkers (Fremont, CA); BRCA1, -tubulin, and phosphotyrosine (PY20)
from Santa Cruz Biotechnologies (Santa Cruz, CA); HER2 (clone 2F12; Up-
state, Lake Placid, NY); GFP (Chemicon, Temecula, CA); WWP1 (44); or
EGFR (C-22) (43). Western blots were developed by using enhanced chemilu-
minescence (Amersham Life Sciences, Arlington Heights, IL).
Microscopy and image acquisition. Cells grown on coverslips were fixed in
3.7% formaldehyde and stained with rabbit anti-HER4 antibody (Santa Cruz
Biotechnologies), mouse anti-HER4 antibody (HFR-1), or mouse anti-Flag an-
tibody, using the following secondary antibodies: fluorescein isothiocyanate-
conjugated donkey anti-rabbit immunoglobulin G (IgG), and rhodamine red-
conjugated donkey anti-mouse IgG (Jackson Immunoresearch Laboratories).
Nuclei were counterstained with DAPI (4,6-diamidino-2-phenylindole; 20 ng/
ml). Slides were mounted with fluorescent mounting medium (DakoCytomation)
and examined by using the Leica SP2 laser scanning confocal microscope with
a 63 oil NA 1.40 Plan Apo lens (Nikon). Images were acquired and processed
by using Leica Confocal software. Minimal image processing was performed with
Adobe Photoshop.
qRT-PCR. Quantitative reverse transcription-PCR (qRT-PCR) was per-
formed as described previously (13). Briefly, total RNA was isolated from HC11
cells stably expressing GFP or GFP-s80HER4 by using an RNeasy kit (Qiagen)
and was treated with RNase-free DNase (Ambion). WWP1 or Nedd4 primers
and intervening fluorescent dye-labeled probes were designed by using Primer
Express software (ABI/Perkin-Elmer). Total RNA (10 ng) isolated from each
cell line was assayed by real-time fluorescence qRT-PCR using an ABI Prism
7900 instrument (PE Bio). The relative abundance of WWP1 or Nedd4 transcript
was calculated by the formula: relative mRNA level 	 e(40
Ct).
In vivo ubiquitination assays. Cells were pretreated with 25 M MG-132 for
5 h and then lysed in RLB buffer containing 1% SDS. Protein samples were
diluted 1:10 and immunoprecipitated with anti-HER4 antibody. Immunoprecipi-
tates were washed and prepared for immunoblot analysis.
RESULTS
Overexpression of s80HER4 increases WWP1 mRNA. HC11
mouse mammary cells stably expressing GFP, or GFP-tagged
s80 HER4 (GFP-s80HER4), were analyzed by cDNA microar-
ray. The initial microarray showed a marked elevation of the
transcript for WWP1 in the GFP-s80HER4 cell. Upon repeat in
triplicate, transcript levels of WWP1, a member of the Nedd4
family of E3 ligases was still elevated in GFP-s80-expressing
cells compared GFP-expressing cells, whereas the expression
levels of other Nedd4 family members were similar in cells
expressing GFP-s80 and GFP (Fig. 1A). Analysis by qRT-PCR
confirmed that the levels of WWP1 mRNA levels, but not of
Nedd4 mRNA, increased in GFP-s80 expressing HC11 cells
over GFP-expressing cells (Fig. 1B). Thus, in cells expressing a
HER4 Cyt1 isoform proteolytic product, s80HER4, which slows
HC11 cell growth (13), one member of an E3 ligase family
exhibited increased steady-state mRNA levels.
WWP1 expression decreases HER4 stability. Based on the
known role of WWP1 as an E3 ubiquitin ligase, which can
target proteins for proteosomal degradation, we determined
the effects of WWP1 expression on HER4 stability. COS-7
cells were cotransfected with pcDNA3-HER4 (JM-a, Cyt1)
and increasing amounts of pcDNA3-Flag-WWP1. The expres-
sion of Flag-WWP1 substantially decreased HER4 protein lev-
els (Fig. 1C). We examined the stability of HER4 protein by
treating the cells with CHX, an inhibitor of new protein syn-
thesis, for 0, 2, 4, or 6 h. Approximately 80% of the total HER4
was degraded in the presence 0.3 g of Flag-WWP1 6 h after
CHX treatment compared to 40% degradation in the absence
of Flag-WWP1 (Fig. 1D).
To determine whether WWP1 affects HER4 levels in a cell
in which HER4 exhibits biologic activity, we examined the
effects of transient WWP1 overexpression on stability of en-
dogenous HER4 in MCF7 breast cancer cells. Transient over-
expression of Flag-WWP1 in MCF7 cells resulted in dimin-
ished levels of HER4 protein, compared to cells expressing
empty vector (Fig. 1E). Using siRNAs to reduce endogenous
WWP1 expression in MCF7 cells, we found that reduction of
endogenous WWP1 correlated with an significant increase
(P 	 0.034 by using the Student t test) in endogenous MCF7
HER4 protein levels (Fig. 1F and G). These results demon-
strate that WWP1 can regulate HER4 protein levels and that
endogenous WWP1 may play a role in HER4 turnover in
breast cells.
error of the mean (SEM). (B) Relative mRNA levels of WWP1 and Nedd4 as determined by qRT-PCR. HC11 cells stably expressing GFP, or
GFP-s80HER4 were used to extract RNA. Experiments were performed in triplicate. Values are expressed as the average of the ratios of the mRNA
levels of WWP1 or Nedd4 in GFP-s80-expressing cells versus GFP-expressing cells plus the SEM. (C) WWP1 promotes HER4 degradation. COS-7
cells transfected with HER4 and increasing amounts of WWP1 were lysed 40 h after transfection. Western analysis of lysates was performed using
anti-HER4, anti-Flag antibody, and anti--tubulin antibody. (D) COS-7 cells transfected with HER4 and pcDNA3 or pcDNA3-Flag-WWP1. After
24 h, CHX was added for 0, 2, 4, or 6 h. Lysates were analyzed by Western blotting with the indicated antibodies. (E) MCF7 cells transfected with
vector or Flag-WWP1 by electroporation were lysed 48 h after transfection. Lysates were analyzed by Western analysis with the indicated
antibodies. (F) MCF7 cells were transfected with control or WWP1 siRNA by electroporation. After 48 h, cell lysates were analyzed by Western
blotting with the indicated antibodies. (G) Densitometry of HER4 expression by Western blotting in MCF7 cells transfected with control or WWP1
siRNA by electroporation. The values are normalized with -tubulin levels and the means of three experiments plus the SEM.
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Subcellular localization of HER4 and WWP1. Dual immu-
nofluorescence of transfected COS-7 cells showed that over-
expressed HER4 and WWP1(CA) colocalized in perinuclear
area, on the cell plasma membrane, and in a punctate pattern
throughout the cytoplasm (Fig. 2A). Using MCF-7 cells (hu-
man breast cancer-derived cells), which express endogenous
HER4 and WWP1, we examined that subcellular localization
of each endogenous protein. Dual immunofluorescence con-
firmed that both endogenous WWP1 and HER4 localized
strongly at the cell periphery of MCF7 cells (Fig. 2B).
HER4 and WWP1: hierarchy of WW domain binding. HER4
and WWP1 form a physical complex, COS-7 cells were trans-
fected with HER4 or Flag-WWP1 alone or cotransfected with
HER4 and Flag-WWP1 or with HER4 and Flag-WWP1(CA),
a site-directed mutant of WWP1 that allows WW domain in-
teractions but that harbors a Cys890-to-Ala mutation abolish-
ing ubiquitin ligase activity. Reciprocal immunoprecipitation
demonstrated that HER4 antibodies precipitated both Flag-
WWP1 and Flag-WWP1(CA) and anti-Flag antibodies precip-
itated HER4 (data not shown).
WWP1 is a E3 ubiquitin ligase containing a C2 domain, four
WW domains, and a HECT catalytic domain. In a previous
study, a series of WWP1 deletion constructs were generated to
map the domain of WWP1 responsible for binding to TGIF
(44). The series of deletion constructs included C2-WW1/4,
WW1/4, and WW1/4-HECT, which retained their WW do-
mains, and C2 and HECT, which contained no WW domain
(Fig. 3). To determine whether the WW domains of WWP1 are
responsible for binding HER4, COS-7 cells were cotransfected
with HER4 and Flag-WWP1(CA) or the series of Flag-tagged
WWP1 deletion constructs (44), and their interactions were
tested. Immunoprecipitation with anti-HER4 antibody precip-
itated WWP1(CA), C2-WW1/4, WW1/4, and WW1/4-HECT,
in which WW domains were included, but not C2 and HECT
in which the WW domains were deleted (Fig. 3). Similarly, in
immunoprecipitation with anti-Flag antibody, only WWP1(CA), C2-
WW1/4, WW1/4, and WW1/4-HECT, but not C2 and HECT,
precipitated HER4 (data not shown). Thus, the WW domains
of WWP1 are responsible for the interactions with HER4. Of
particular interest was the construct WW1/4-HECT, which de-
leted phospholipid-binding domain C2 while retaining WW
domains. This construct continued to bind to HER4.
To determine the HER4 domain responsible for interaction
with WWP1, we generated a series of HER4 deletion con-
structs, each tagged with GFP. These constructs included the
HER kinase domain only (GFP-KDOHER4, amino acids 676 to
995), the C terminus of HER4 (GFP-CTHER4, amino acids 989
to 1308), the entire intracellular cytoplasmic domain of HER4
(GFP-s80HER4, amino acids 676 to 1308), and kinase-dead GFP-
s80HER4 (single-amino-acid mutation K751R, GFP-s80KRHER4)
(Fig. 4A). COS-7 cells were cotransfected with WWP1(CA) and
vectors expressing the HER4 deletion constructs. Immunopre-
cipitation with Flag antibodies demonstrated that the HER4 C
terminus (GFP-CTHER4) coprecipitated with Flag-WWP1(CA),
as did the entire HER4 intracellular domain (GFP-s80HER4). In
contrast to the need for kinase activity for nuclear translocation,
the WWP1-HER4 interaction was not dependent upon kinase
activity or tyrosine phosphorylation of the HER4 intracellular
domain, since the kinase inactive GFP-s80KRHER4 coprecipi-
tated with Flag-WWP1(CA) (Fig. 4A). A construct consisting of
FIG. 2. Subcellular localization of HER4 and WWP1. (A) COS-7 cells were cotransfected with full-length HER4 and Flag-WWP1(CA). After
24 h, cells were immunostained with rabbit anti-HER4 antibody and mouse anti-Flag antibody, and fluorescence-conjugated secondary antibodies.
(B) MCF7 cells were immunostained with rabbit anti-WWP1 antibody and mouse anti-HER4 antibody and then with fluorescence-conjugated
secondary antibodies to detect localization of endogenous WWP1 and HER4.
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the HER4 kinase domain (GFP-KDOHER4) without the C ter-
minus did not coprecipitate with Flag-WWP1(CA). These data
are consistent with the location of the three putative WW-domain
binding regions of HER4, PY1, PY2, and PY3, each located
within the C-terminal fragment of HER4 and absent in GFP-
KDOHER4.
Because one of the putative PY domains, PY2, resides
within the 16-amino-acid region that is specific to s80Cyt1 (i.e.,
it is absent in s80Cyt2), we compared the coprecipitation of
s80Cyt1 with Flag-WWP1(CA) to that of s80Cyt2. Both
s80Cyt1 and s80Cyt2 were found in anti-Flag immunoprecipi-
tates. However, s80Cyt1 was present in greater amounts in the
coimmunprecipitates, even though s80Cyt1 and s80Cyt2 were
expressed at similar levels (Fig. 4B).
To determine whether the PY1 and PY3 domains are re-
quired for interactions with WWP1(CA), we introduced dele-
tion mutations into s80Cyt2, such that s80Cyt2PY1 lacks both
PY1 and PY2, s80Cyt2PY3 lacks both PY2 and PY3, and
s80Cyt2PY1,3 lacks all PY motifs (Fig. 4B). Deletion of the
PY1 domain from s80Cyt2 did not greatly affect the presence
of s80Cyt2 in Flag-WWP1 immunocomplexes. In contrast, de-
letion of the PY3 domain from s80Cyt2 substantially reduced
the coprecipitation of s80 with Flag-WWP1(CA). Deletion of
both PY1 and PY3 from s80Cyt2 completely abolished the
interaction between s80Cyt2 and Flag-WWP1(CA) (Fig. 4B).
From these data, we may infer that the capability of each PY
motif to bind WWP1 is PY2  PY3  PY1.
Previous reports described an interaction between the WW
domain containing protein YAP and HER4 mediated through
the PY3 motif of HER4; PY1 was dispensable for the HER4-
YAP interactions (23). The authors of that study did not ex-
amine whether the PY2 motif, unique to s80Cyt1 and absent in
s80Cyt2, mediated HER4 and YAP binding. To test the hier-
archy of binding in another WW domain protein, we cotrans-
fected s80Cyt1 and s80Cyt2 and hemagglutinin-tagged Yap2
(HA-Yap2), in COS-7 cells. Both s80Cyt1 and s80Cyt2 copre-
cipitated with HA-Yap2; however, s80Cyt1 coprecipitated with
HA-Yap2 in greater abundance than s80Cyt2, even though
both proteins were expressed at similar levels. This suggests
that PY2 interacts more strongly in HER4-Yap2 interaction.
We confirmed the previous reports that the PY3 motif is re-
quired for s80Cyt2-Yap2 interaction, since s80Cyt2PY3 did
not coprecipitate with HA-Yap2. The converse experiment, in
which HER4 immunoprecipitates were analyzed by Western
blotting with an anti-HA antibody, confirmed that loss of the
PY2 domain alone reduced s80HER4 interaction with HA-
Yap2 and that loss of both PY2 and PY3 together eliminated
interaction between HA-Yap2 and s80HER4 (Fig. 4C).
We also used this set of HER4 constructs to examine bind-
ing between HER4 and Wwox, another WW domain-contain-
FIG. 3. WW domains of WWP1 are responsible for binding HER4. (Left panel) Schematic diagram of WWP1, mutated WWP1, and a series
of WWP1 deletion constructs. (Right panel) COS-7 cells were cotransfected with HER4 (JMa-Cyt1) and different Flag-tagged WWP1 constructs
as indicated. Cells were lysed 24 h after transfection. Cell lysates were immunoprecipitated with anti-HER4 antibody and analyzed by Western
analysis with indicated antibodies. The lysates were also directly used for Western analysis to detect the expression levels of indicated proteins.
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FIG. 4. WWP1 requires the PY2 and PY3 motifs in the C terminus of HER4 for interaction with HER4. (A) The upper panel shows a schematic diagram
of HER4 and a series of HER4 deletion or mutation constructs used for expression in COS-7 cells. In the lower panel, COS-7 cells were cotransfected with
Flag-WWP1(CA) (1 g) and different GFP-tagged construct (3 g of each) as indicated. Cells were lysed 24 h after transfection. Lysates were used for Western
analysis where indicated, or were immunoprecipitated with anti-Flag antibody and analyzed by Western blotting. (B) In the upper panel, a series of deletion
mutations were made within s80Cyt2 to delete the PY1 motif, the PY3 motif, or both. These were used for expression in COS-7 cells, as were expression
constructs encoding s80Cyt1, s80Cyt2, and full-length HER4 (JM-a, Cyt1). In the lower panel, COS-7 cells were cotransfected with 1 g of Flag-WWP1(CA)
and 3 g of empty vector, full-length HER4, s80Cyt1, s80Cyt2, s80Cyt2PY1, s80Cyt2PY3, or s80Cyt2PY1,3. The cells were lysed 24 h after transfection.
Anti-Flag antibody and anti-HER4 antibody immunoprecipitates were analyzed by Western analysis as indicated. (C) Interaction of HER4 and Yap2. COS-7
cells were cotransfected with 2.5 g of HA-Yap2 and 3 g of empty vector, full-length HER4, s80Cyt1, s80Cyt2, s80Cyt2PY1, s80Cyt2PY3, or
s80Cyt2PY1,3. After 24 h, HER4 and HA immunoprecipitates were analyzed by Western blotting with the indicated antibodies. (D) COS-7 cells were
cotransfected with 2.5 g of Flag-Wwox and 3 g of empty vector, full-length HER4, s80Cyt1, s80Cyt2, s80Cyt2PY1, s80Cyt2PY3, or s80Cyt2PY1,3. After
24 h, HER4 and Flag immunoprecipitates were analyzed by Western blotting with the indicated antibodies.
898
ing protein known to bind to HER4 (1, 2). Anti-Flag immu-
noprecipitates from COS-7 cells transfected with vectors
expressed Flag-tagged Wwox (Flag-Wwox) were analyzed by
Western blotting with HER4 antibodies. In contrast to WWP1
and Yap2, Flag-Wwox bound to full-length HER4Cyt1,
s80Cyt1, and s80Cyt2 similarly. Binding between Flag-Wwox
and HER4 diminished when PY1 and PY2 were deleted. Flag-
Wwox and s80 binding was minimal if PY2 and PY3 were
deleted and s80 and Wwox interaction was abolished upon the
loss of all three PY motifs (Fig. 4D).
Taken together, these data indicate that the PY3 interacts
with the WW domain of WWP1, YAP, and Wwox and that
PY1 is less important for all three donor proteins. The fact
that Wwox bound similarly to s80Cyt1 and s80Cyt2 indicates
that binding to PY3 is the most important for WWOX. How-
ever, WWP1 and Yap2 displayed decreased binding to s80Cyt2
compared to s80Cyt1, suggesting that PY2 is more important
for Yap2 or WWP1 HER4 interactions.
WWP1 is specific for HER4. We examined the stability of
EGFR family members in the presence or absence of WWP1.
Although transient coexpression of HER4 with increasing
amounts of WWP1 reduced HER4 protein levels in a dose-
dependent manner, the protein expression levels of EGFR,
HER2, and HER3 were not affected by WWP1 coexpression
(Fig. 5A). This selectivity indicates that WWP1 is potentially
one of the factors that regulate HER4 biologic action, as dis-
tinct from other family members. In addition, HER4 receptor
tyrosine phosphorylation correlated directly with total receptor
expression, suggesting that WWP1 expression affects the total
levels of HER4 receptor expression but does not impair HER4
tyrosine kinase activity or tyrosine phosphorylation (Fig. 5A).
Interestingly, when Flag-WWP1 was coexpressed with HER4,
WWP1 protein was markedly diminished compared to WWP1
levels after coexpression with EGFR, HER2, and HER3 (Fig.
5B). Increasing amounts of HER4 protein expression de-
creased the WWP1 protein level in a dose-dependent manner
(Fig. 5C), suggesting that HER4 and WWP1 are both de-
graded following their interaction. This type of codegradation
has been observed for other E3 ligase substrate pairs (62). The
physiologic significance of this feedback or autodegradation is
thought to allow the cells to reaccumulate the substrate.
WWP1-dependent degradation is greater for membrane-as-
sociated full-length and 80-kDa HER4 than for soluble 80-kDa
HER4. HER4 JM-a isoforms, but not JM-b isoforms, can be
cleaved by TACE into m80HER4 (40, 54). An unknown pro-
portion of m80HER4 is further cleaved into s80HER4 by -secre-
tase (34). To determine whether WWP1 induces degradation
of s80HER4, we transfected COS-7 cells with increasing
amounts of Flag-WWP1 and HER4 or s80HER4. Western blot-
ting showed that WWP1 more effectively induced degradation
of full-length HER4 than s80HER4 (Fig. 6A). To determine
whether WWP1 induces degradation of GFP-s80HER4. We
transfected COS-7 cells with increasing amounts of Flag-
WWP1 and HER4, s80HER4, or GFP-s80HER4. Western blot-
ting showed that WWP1 more effectively induced degradation
of full-length HER4 than s80HER4 or GFP-s80HER4 (Fig. 6B).
Next, we transfected COS-7 cells with HER4 and increasing
amounts of Flag-WWP1. After 40 h, the cells were treated with
100 ng of PMA/ml for 1 h to increase the formation of
m80HER4. The cells were then lysed and separated into mem-
brane and soluble fractions by ultracentrifugation. Western
blot showed that membrane-bound 80-kDa HER4 was suscep-
tible to WWP1-induced degradation (Fig. 6C). s80HER4 was
not observed, presumably because it is made in small amounts
under these conditions. WWP1 was found predominantly in
the membrane fraction (Fig. 6C). There is a C2 phospholipid
binding domain at the N terminus of WWP1 (14), which may
explain the propensity of WWP1 to distribute to the membrane
fraction. This localization might also indicate why s80HER4 is
less susceptible to WWP1-induced degradation, although when
overexpressed by transfection the two entities can bind to each
other (Fig. 4). To test the specificity of WWP1-mediated deg-
radation for m80HER4, We made an m80 construct (HER4
residues 632 to 1308, including the transmembrane domain).
We transfected COS-7 cells with increasing amounts of full-
length Flag-WWP1 and m80 or s80. WWP1 again more effec-
tively promoted the degradation of m80 compared to s80 (Fig.
6D). To explore this further, increasing amounts of Flag-WW1/
4-HECT, a WWP1 fragment without C2 domain but with
HER4 binding and ligase capability, were transfected into
COS-7 cells with HER4 or s80. As shown in Fig. 6E, Flag-
WW1/4-HECT (without C2) more efficiently promoted s80
degradation than full-length HER4 or PMA induced m80
HER4 degradation. This suggests that the specificity for mem-
brane bound HER4 (full length and m80) is dictated by the
membrane association of WWP1 (produced by the C2 do-
main). Overexpression of a soluble (C2-deleted WWP1) will
FIG. 5. WWP1 promotes degradation of HER4 but not EGFR,
HER2, or HER3. (A) COS-7 cells were transfected with increasing
amounts of Flag-WWP1 (0, 0.1, 0.3, or 1 g) and HER4, EGFR,
HER2, or HER3. After 40 h, lysates were analyzed by Western blotting
with the indicated antibodies. (B) COS-7 cells were cotransfected with
Flag-WWP1 and vector, EGFR, HER2, HER3 or HER4. After 40 h,
lysates were analyzed by Western blotting with the indicated antibod-
ies. (C) COS-7 cells were cotransfected with Flag-WWP1 and increas-
ing amounts of HER4. After 40 h, lysates were analyzed by Western
blotting with the indicated antibodies.
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allow s80 degradation, but this is not the normal state of the
cell. Many of our experiments point to an efficient membrane
complex in breast cells that enhance WWP1 and regulates
HER4 levels.
WWP1 expression directs proteosomal degradation of mem-
brane bound 80-kDa HER4, and full-length HER4 degrada-
tion is less dependent on the proteosome. To determine the
mechanism of WWP1-dependent decreased HER4 stability,
we coexpressed full-length HER4 (JM-a, Cyt1) and increasing
amounts of Flag-WWP1 in COS-7 cells. After 24 h cells were
treated or not treated with the proteasome inhibitor MG132.
Proteosome inhibition had little effect on WWP1-dependent
HER4 loss but markedly increased accumulation of 80-kDa
HER4 species (on a gel one cannot distinguish the membrane-
bound m80, which had not undergone the -secretase cleavage
or the soluble s80, which has undergone the second cleavage).
However, while proteosomal inhibition markedly alternated
80-kDa HER4 degradation, it did not completely block this
WWP1-induced effect (Fig. 7A). Interestingly, proteosomal in-
hibition increased the accumulation of m80/s80 HER4 even in
the absence of exogenous WWP1 expression, suggesting that,
at least in COS-7 cells, the HER4 cleavage product (presum-
ably m80) is made constitutively at some rate and is the target
of proteosomal degradation. Whether this is the result of en-
dogenous E3 ubiquitin ligases, such as WWP1, is not yet
known.
We next examined the effects of the lysosome inhibitor
bafilomycin A1 on HER4 stability. Although bafilomycin A1
increased m80/s80HER4 accumulation to some extent, MG132
and bafilomycin A1 together resulted in substantially increased
m80/s80 accumulation (Fig. 7B). These data suggest that the
proteasomal and lysosomal degradation pathways may each
participate in m80/s80HER4 destruction.
Metalloprotease activity, i.e., TACE, is involved in the cleav-
age of HER4 to form m80HER4 (40, 54). To determine whether
metalloprotease cleavage of HER4 was required for WWP1-
induced HER4 degradation, we coexpressed HER4 (JM-a,
Cyt1) with increasing levels of Flag-WWP1, treating the cells
with or without the metalloprotease inhibitor GM6001. As
expected, GM6001 decreased the accumulation of m80/s80
HER4, resulting in the persistence of full-length HER4 (Fig.
7C). However, GM6001 did not block WWP1-induced HER4
degradation, suggesting that cleavage of full-length HER4 by
TACE is not a prerequisite to WWP1-induced HER4 degra-
dation.
To determine whether tyrosine phosphorylation of HER4
affects WWP1-induced HER4 degradation, we expressed Flag-
WWP1 with wild-type or kinase-dead HER4. WWP1 pro-
moted the degradation of both wild-type and kinase-dead
HER4 similarly (Fig. 7D).
Previous reports demonstrated that PMA can activate
TACE in the absence of HER4 activity. Thus, PMA treatment
bypasses the requirement for HER4-induced TACE activation,
and results in the generation of m80 independently of HER4
kinase activity (54). In agreement with previous work, PMA
induced the formation of m80 HER4 from kinase-dead HER4.
However, this m80HER4 product was degraded in a WWP1-
dependent manner. As the opposite of GM6001, PMA accel-
erated WWP1-induced degradation of full-length HER4 (ki-
nase active or kinase inactive) (Fig. 7D and data not shown).
Taken together, these data indicate that proteosomal and
lysosomal pathways contribute to the degradation of m80/
s80HER4 but are less involved in full-length HER4 degradation.
This full-length HER4 is degraded in response to WWP1 by
other unknown mechanisms that do not require HER4 ty-
rosine kinase activation or TACE-mediated HER4 cleavage.
WWP1 ubiquitinates HER4 and causes HER4 degradation.
Because WWP1 is an E3 ubiquitin ligase and associates with
HER4, we used transient expression of HER4 and WWP1 in
COS-7 cells to determine whether their coexpression results in
the ubiquitination of HER4. Immunoprecipitation of HER4
from MG132-treated cells revealed ubiquitinylated HER4
when expressed in the presence of Flag-WWP1 but not in the
presence of Flag-WWP1(CA), the mutant isoform of WWP1
that binds to HER4 but lacks E3 ubiquitin ligase activity (Fig.
8A). We used WWP1(CA) expression to determine whether
ubiquitin ligase activity of WWP1 is required for WWP1-me-
diated HER4 degradation. Although Flag-WWP1 resulted in
the decreased presence of HER4 in COS-7 cells, increasing
levels of exogenous Flag-WWP1(CA) expression resulted in
the accumulation of full-length HER4 and 80-kDa HER4
(Fig. 8B). These results demonstrate that WWP1-mediated
ubiquitination is required for HER4 degradation.
Expression of exogenous WWP1 downregulates HER4-in-
duced functions. Previous studies have shown that STAT5-
dependent promoters, such as the -casein promoter, are stim-
ulated by heregulin (HRG)-dependent activation of HER4
(33). To determine whether WWP1 overexpression affects bi-
ological consequences of HER4 activation, MCF7 cells were
cotransfected with a -casein promoter-luciferase reporter
plasmid (33) and either pcDNA3-WWP1 or empty pcDNA3.
Transfected cells were treated with or without heregulin for
FIG. 6. Soluble 80-kDa HER4 is less susceptible to WWP1-induced degradation than full-length HER4 and membrane-bound 80-kDa HER4.
(A) COS-7 cells were transfected with increasing amounts of Flag-WWP1 (0, 0.1, 0.3, and 1 g) and 3 g of HER4 or s80HER4. After 40 h, lysates
were analyzed by Western blotting with the indicated antibodies. (B) COS-7 cells were transfected with increasing amounts of Flag-WWP1 (0, 0.2,
and 1 g) and 3 g of HER4, s80HER4, or GFP-s80HER4. After 40 h, lysates were analyzed by Western blotting with the indicated antibodies.
(C) COS-7 cells were transfected with HER4 and increasing amounts of Flag-WWP1 (0, 0.2, and 1 g). After 40 h, the cells were treated with 100
ng of PMA/ml for 1 h to increase the formation of 80-kDa membrane-associated HER4. The cells were then lysed, and the lysates were separated
into membrane and soluble fractions by ultracentrifugation. Western blot analysis was performed with anti-Flag antibody. Membrane and soluble
fractions were further lysed with 1% Triton X-100, immunoprecipitated, and analyzed by Western blotting with an anti-HER4 antibody. (D) COS-7
cells were transfected with increasing amounts of Flag-WWP1 (0, 0.2, and 1 g) and 3 g of m80HER4 or s80HER4. After 40 h, the cells were lysed
and lysates were analyzed by Western blotting with the indicated antibodies. (E) COS-7 cells were transfected with increasing amounts of
Flag-WW1/4-HECT lacking the C2 membrane association domain (0, 0.2, and 1 g) and 3 g of HER4 or s80HER4. After 40 h, the cells transfected
with HER4 were treated with 100 ng of PMA/ml for 1 h to increase the formation of 80-kDa membrane-associated HER4. All of the cells were
then lysed, and lysates were analyzed by Western blotting with the indicated antibodies.
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48 h, which has been previously shown to induce HER4-de-
pendent activation of this promoter (33). HRG-treated cells
transfected with pcDNA3 displayed a 19-fold increase in lucif-
erase activity versus untreated cells (Fig. 9A), a finding con-
sistent with previous reports (33). However, cells overexpress-
ing WWP1 responded to HRG with only an eightfold increase
in luciferase activity (Fig. 9A). Because previous studies have
shown that HRG-induced activation of HER4 results in acti-
vation of this promoter and because increased WWP1 expres-
sion results in the targeted degradation of HER4 in these cells,
the results presented here are consistent with the idea that
WWP1 expression antagonizes the biological consequences of
HER4 signaling, likely through its ability to decrease total
HER4 levels.
Previous studies suggest that heregulin induces the expres-
sion of BRCA1 mRNA and protein in breast cancer cells in a
HER4-dependent, but HER2-independent manner (31). Be-
cause this heregulin-induced effect is specifically dependent on
HER4, we were interested to determine whether increased
expression of WWP1 impaired the induction of BRCA1 in
response to ligand activation of HER4. We generated MCF-7
cells stably expressing WWP1 (Fig. 9B). The cells were treated
with or without heregulin for 24 h. Expression of WWP1 was
not affected by treatment with heregulin for 24 h. While
heregulin increased BRCA1 protein levels in parental MCF7
cells, BRCA1 levels were unchanged in response to heregulin
in the cells overexpressing WWP1 (Fig. 9B). To determine
whether eliminating endogenous WWP1 enhances the induc-
tion of BRCA1 in response to ligand-activated HER4, we
“knocked down” WWP1 by using an siRNA approach. MCF7
cells were transfected by electroporation with control siRNA
oligonucleotides or WWP1 specific siRNA oligonucleotides.
Decreased WWP1 protein was seen in MCF7 cells transfected
with WWP1-specific sequences but not in cells transfected with
control siRNA sequences. Elimination of WWP1 correlated
with a 30% increase in HER4 protein levels (see Fig. 1F and
FIG. 7. Proteosomal and lysosomal degradation of m80/s80 HER4. (A and B) COS-7 cells were transfected with HER4 and increasing amounts
of Flag-WWP1. After 24 h, the cells were treated with or without proteasome inhibitor MG132 for 5 h (A) or treated with or without the lysosome
inhibitor bafilomycin A1 or bafilomycin A1MG132 for 5 h (B). Lysates were analyzed by Western blotting with the indicated antibodies.
(C) COS-7 cells were transfected with HER4 and increasing amounts of Flag-WWP1. After 40 h, cells were treated with or without GM6001 for
5 h. Lysates were analyzed by Western blotting with the indicated antibodies. (D) COS-7 cells were transfected with increasing amounts of
Flag-WWP1 and HER4 or kinase-dead HER4. After 40 h, the cells transfected with kinase-dead HER4 were treated with or without 100 ng of
PMA/ml for 30 min (where indicated). The cells were then lysed, and the lysates were processed as described in panel C.
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G). However, the heregulin-dependent elevation of BRCA1
was similar in the presence or absence of WWP1 (Fig. 9C).
Therefore, the 30% increase in HER4 expression may not be
sufficient to further increase HRG-induced BRCA1 induction.
In contrast, overexpression of exogenous WWP1 eliminated
HER4 expression in MCF7 cells (Fig. 1E) and eliminated the
HER4-dependent induction of BRCA1 expression in response
to heregulin. Alterations in WWP1 signaling may impact pro-
tein levels of BRCA1 by alternate signaling pathways, a possi-
bility that is not ruled out by the results presented here. How-
ever, because the heregulin-induced endpoints are specifically
HER4 dependent and because basal levels of BRCA1 expres-
sion and -casein promoter activation were unaffected in un-
treated WWP1-expressing cells compared to untreated paren-
tal cells, it is clear that HER4-directed signaling is attenuated
by WWP1.
DISCUSSION
We have shown here that the E3 ligase, WWP1, ubiqui-
tinates HER4, targeting it for degradation through the proteo-
somal and lysosomal pathways. Although other E3 ligases are
known to target EGFR family members for degradation,
WWP1 demonstrates specificity within the EGFR family for
HER4. This specificity is driven by three PY motifs, or WW-
domain binding motifs, which are present in HER4 but are
absent in other EGFR members.
By targeting HER4 for degradation, WWP1 expression has
a negative impact on the biologic consequences of HER4 ac-
tivity, such as lactogenic differentiation (as measured by -ca-
sein promoter activity [Fig. 9A]), or regulation of BRCA1
expression, which we have postulated is important in HER4-
dependent growth inhibition (31) (Fig. 9B). Increased differ-
entiation and decreased growth of breast cells can occur in
response to HER4 Cyt1 activity (13, 33, 43) and are consistent
with the observations that HER4 expression in breast cancers
generally correlates with a more favorable prognosis (3, 21, 37,
46, 51, 52, 57). The results presented here suggest that in-
creased expression of WWP1 may counteract the potential
tumor suppressor effects of HER4 in breast cancers (see ref-
erence 48). Interestingly, not all studies of HER4 in breast
cancer suggest that HER4 correlates with a favorable progno-
sis (4, 27). The reason for this discrepancy is unknown but may
relate to alternative HER4 splicing. In fact, some studies have
shown altered signaling potential and increased stability of the
HER4Cyt2 isoform compared to HER4Cyt1 (50). Interest-
ingly, the PY2 motif of HER4 is only present in the Cyt1 splice
variant. The absence of PY2 in the HER4Cyt2 variant appears
to decrease interaction with WWP1, rendering HER4Cyt2 less
susceptible to downregulation by WWP1. Decreased interac-
tion between HER4Cyt2 and WWP1 may explain in part the
enhanced stability of HER4Cyt2 over HER4Cyt1. Likewise,
the different biologic outcomes between Cyt1 and Cyt2 HER4
may also be due to a decreased association of the Cyt2 isoform
with YAP as our data show for the first time (Fig. 4C). The
PY3 motif of HER4 (present in both Cyt1 and Cyt2) supported
interaction between each of the WW-domain containing pro-
teins tested, including Wwox (Fig. 4), but Wwox interacted
equally with HER4Cyt1 or HER4Cyt2. Thus, Wwox may play
a similar role in the action of both HER4 isoforms. These data
underscore the specificity underlying the overlapping but dis-
tinct functions of these (and perhaps other) WW domain-
containing proteins in HER4 signaling.
WWP1 is a member of Nedd4 family of related E3 ligases,
which also includes Nedd4-1, Nedd4-2, WWP1/Tiul1, WWP2,
Aip4/Itch, Smurf1, Smurf2, HecW1/NedL1, and HecW2/
NedL2 (18). Among the family members, Nedd4, WWP1,
Smurf1, and Smurf2 have been reported to be overexpressed in
FIG. 8. WWP1 ubiquitinates HER4 and causes HER4 degradation. (A) COS-7 cells were transfected with HER4, WWP1, and WWP1(CA).
At 24 h after transfection, the cells were treated with MG132 for 5 h and then lysed in RLB buffer containing 1% SDS. Lysates were used for
Western analysis, or were diluted 1:10, and immunoprecipitated with anti-HER4 antibody, and immunocomplexes were analyzed with the indicated
antibodies. (B) COS-7 cells were transfected with 3 g of HER4 and increasing concentrations (0, 0.2, 1 g) of vectors expressing Flag-WWP1
or Flag-WWP1(CA). After 24 h, the lysates were used for Western analysis as shown or were immunoprecipitated with the indicated antibodies
and analyzed by Western blotting.
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several human cancers (6, 7, 22, 29, 55). It is possible that
overexpression of these factors may contribute to tumorigen-
esis through a negative impact on the balance of tumor sup-
pressors or proteins that promote differentiation, such as
pTEN or p53, through ubiquitination-directed degradation.
This scenario has been proposed for Nedd4, which ubiquiti-
nates the tumor suppressor pTEN, targeting it for degradation
(55). Because pTEN plays a central role in the growth and
survival of prostate and other cancer cells, Nedd4 expression
levels could influence cellular decisions along the pathway to-
ward malignancy. Similarly, WWP1 and Smurfs target Smads
of growth-inhibitory transforming growth factor  (TGF-)
signaling pathway for degradation (5). While TGF- has the
ability to inhibit growth of some tumor cells in a Smad-depen-
dent manner, TGF- signaling also promotes motility and sur-
vival of tumor cells in a Smad-independent manner, thus con-
tributing to malignancy (32). The degradation of Smads as
directed by WWP1 and Smurfs may tilt the balance of the
TGF- signaling pathway toward Smad-independent mecha-
nisms that promote survival and motility and remain un-
checked by growth control (29, 44). It has also been reported
that WWP1 ubiquitinates p53 to prevent its translocation to
nucleus and decrease its transcriptional activities (24).
Consistent with the observation that WWP1 is often over-
expressed in human cancers and may promote tumorigenesis,
the gene for WWP1 is located at 8q21, a region frequently
amplified in human prostate and breast cancer. WWP1 over-
expression promotes prostate and breast cell proliferation and
survival (6, 7), perhaps due to the degradation of one or more
of the WWP1 substrates described above or those unidentified.
Our report that WWP1 is an E3 ligase for HER4, is a new
addition to our understanding on the WWP1’s role in cancer,
especially in breast cancer. HER4 signaling decreases cellular
proliferation of human breast cells and promotes differentia-
tion (13, 33, 38, 43). Our work indicates that this is due to the
action of the Cyt1 isoform (13, 31, 33), the isoform most likely
to be affected by WWP1. In breast cancers, HER4 expression
correlates with the presence of estrogen receptor, a more dif-
ferentiated tumor grade, and longer survival (37, 51, 57). The
studies cited did not have the reagents to distinguish whether
HER4 isoform expressed as Cyt1 or Cyt2. However, degrada-
tion of the HER4 Cyt1 signal caused by WWP1 overexpression
could be another important mechanism of enhanced tumori-
genesis.
Initial reports of m80HER4 production from full-length
HER4 described the rapid ubiquitination and degradation of
FIG. 9. Expression of exogenous WWP1 decreases biological consequences of HER4 activity. (A) MCF7 cells were transfected with pcDNA3
or pcDNA3-Flag-WWP1 and -casein promoter-luciferase reporter plasmid and then treated or not treated with HRG. Luciferase activity was
measured 48 h after transfection and is expressed as relative light units per milligram of total protein. Experiments were performed in triplicate.
Values represent the averages plus the SEM. (B) Parental and Flag-WWP1- expressing MCF7 cells were treated () or not treated (
) with HRG
and lysed, and the lysates were analyzed by Western blotting with the indicated antibodies. (C) MCF7 cells were transfected by electroporation
with control siRNA oligonucleotides or WWP1 specific siRNA oligonucleotides. The cells were then treated with HRG or not treated with HRG
and lysed, and the lysates were analyzed by Western blotting with the indicated antibodies.
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m80HER4. The observation was made that m80 was far more
susceptible to proteosomal degradation than was full-length
HER4 (54). This is similar to our findings that demonstrate
proteosomal/lysosomal degradation of m80 HER4, but un-
known mechanisms of full-length HER4 degradation (Fig. 7).
Most recently, Omerovic et al. screened a brain cDNA phage
library with HER4 peptides and found that Itch could interact
with HER4 and then demonstrated that Itch could ubiquiti-
nate and target HER4 for degradation (36). It is very likely
that both WWP1 and Itch regulate HER4 protein levels via
ubiquitination. Functional redundancy seems to be common
among members of the Nedd4 E3 ligase family. For example,
Smurf1 and Smurf2 can target Smad1, Smad2, and Smad5 for
degradation, and WWP1 targets Smad2 for degradation (5).
Smurf1, Smurf2, and WWP1 each target RUNX2 for ubiq-
uitin-mediated degradation (20, 45, 60). Consistent with the
idea of functional redundancy between WWP1 and Itch, it has
been described (unpublished data referred to in reference 5)
that combined loss of both WWP1 and Itch in genetically
engineered mice resulted in postnatal lethality within 72 h of
birth due to lung hemorrhage, but that single loss of either was
compatible with fetal development. The fact that WWP1
knockdown by siRNA in MCF7 cells increases endogenous
HER4 suggests that, at least in the MCF-7 breast cell, WWP1
may be the relevant E3 ligase and that the Itch and WWP1 may
have tissue or cell-type-specific functions.
Our data do not fully elucidate the “downregulation” mech-
anism involved in HER4 signaling. Our previous results show
that ligand-dependent HER4 signaling in cells can be pro-
longed (33). The data presented here indicate that WWP1
binds to HER4 and is most effective in degrading the mem-
brane-associated species HER4 and m80HER4. WWP1 binds to
s80HER4 but does not appear to promote degradation at the
same rate as the membrane-associated forms. Previous data
suggest that HER4 Cyt1 growth inhibition and differentiation
requires the action of the intracellular s80HER4 derived from
m80HER4 (33, 34). Perhaps one major action of WWP1 is to act
at the membrane to prevent the m80HER4 conversion to
s80HER4 by causing its rapid degradation through a largely
proteosome-dependent process. The elimination of the C2-
membrane association domain of WWP1 (Fig. 6E) reverses the
membrane-soluble HER4 specificity of WWP1. The overex-
pression of soluble WWP1 (without C2) and soluble 80-kDa
HER4 Cyt1 shows that under these conditions the WWP1-
s80HER4 complex can access the degradation machinery effi-
ciently. Under the “normal” circumstance in which WWP1 is
membrane associated via its C2 domain, it appears that a more
efficient degradation of m80HER4 is achieved, presumably
through a membrane complex. What triggers WWP1 activity
toward m80, preventing its prolonged signaling (and subse-
quent stochastic, -secretase-dependent release of the potent
differentiation and growth inhibitory fragment s80HER4), is
unknown. The mechanism of the WWP1’s effect on full-length
HER4 is at least in these experiments less well defined. How-
ever, the fact that s80HER4 expression stimulates WWP1 RNA
accumulation does suggest that a cellular feedback mechanism
exists whereby s80 action would result in more WWP1 (pre-
sumably sent to the membrane) to downmodulate the signal.
In summary, we have demonstrated that WWP1 binds, ubiq-
uitinates, and promotes the degradation of HER4, but not
other members of the EGFR family. Given that HER4 is the
unique member of the EGFR family that decreases growth and
promotes differentiation of breast cells, it will be important to
understand the relationship between HER4 and WWP1, as
well as other WW domain-containing E3 ligases, in breast
cancer. It is conceivable that inhibition of WWP1 activity could
result in the stabilization of HER4 and its cleavage products,
resulting in decreased growth and differentiation of breast can-
cer cells.
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